Independence Day: Toll relief, annual pass for pvt vehicles on highways from 15 Aug

New Delhi: The government on Wednesday announced a FASTag-based annual pass priced at ₹ 3,000, effective from 15 August, offering commuters relief from having to paying frequent hefty toll charges on national highways.
The new pass, which will be valid for a year from the date of activation or 200 trips—whichever comes first—is designed exclusively for non-commercial private vehicles such as cars, jeeps, and vans to facilitate hassle-free, faster and smoother travel experience for millions, minister of road transport and highways Nitin Gadkari said in a post on X.
'In a transformative step towards hassle-free highway travel, we are introducing a FASTag-based Annual Pass priced at F3,000, effective from 15th August 2025… The Annual Pass will enable seamless and cost-effective travel across National Highways throughout the country.
A dedicated link for activation and renewal will soon be made available on the Rajmarg Yatra App as well as on the official websites of NHAI and MoRTH,' Gadkari said.
Mint reported in February on a plan for annual discounted toll passes for private vehicles on national highways.
Travellers will also get a discount on the toll on certain national highway stretches.
'This policy addresses long-standing concerns regarding toll plazas located within a 60 km range and simplifies toll payments through a single, affordable transaction. By reducing wait times, easing congestion, and minimizing disputes at toll plazas, the Annual Pass aims to deliver a faster and smoother travel experience for millions of private vehicle owners,' the minister's post said.
The move follows rising concern over high toll charges on Indian highways. Several new stretches have a string of toll booths that make travelling on them extremely expensive for both personal and commercial vehicles.
It is estimated that toll charges for a one-way journey on the 1,386-km Delhi-Mumbai expressway, which is still under construction, could range between ₹ 1,000 and ₹ 3,000 depending on the type of vehicle.
The toll is determined on the basis of distance as well as the road structure. For instance, it is higher on routes with more railway overpasses. Toll charges grew by over 3% in FY25 and are projected to grow by 3.5-4.2% in FY2026, according to an Icra report.
The annual pass has been designed in a way that it does not impact the revenue of concessionaires operating highway stretches. This means that any loss in projected revenue from highway stretches would be covered by the government.
The toll pass could significantly reduce travel costs for frequent commuters and enhance ease of movement. Several states, including Maharashtra and Tamil Nadu, have already tried out monthly toll passes, which demonstrated their feasibility.
The loss of revenue from discounting is expected to be limited given that private vehicles contribute just about 26% of annual toll collection, while 74% share is with commercial vehicles.
The user fee collection or toll collection at plazas on national highways stood at ₹ 55,882.12 crore in FY24. This was a jump over the ₹ 48,032.40 crore collected in FY23 and ₹ 33,928.66 crore in FY22.
In FY25, the ministry of road transport and highways is targeting toll collection of ₹ 70,000 crore. As on October, 2024, there were a total of 1,015 user-fee plazas on national highways. A 3-5% traffic growth is likely to see toll collection grow by 7-9% in FY2026, the Icra report said.
The ministry will also implement a barrier-less global navigation satellite system (GNSS)-based toll collection system on certain stretches of national highways as an added facility along with FASTag.
A GNSS-based toll collection system would do away with the need for toll plazas on those highways stretches, facilitate smooth movement of vehicles and enable distance-based tolling so users pay only for the stretches they have travelled.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Mint

28 minutes ago

• Mint

Perplexity Labs to make sense of scattered user feedback

Product teams regularly face a challenge: User feedback is scattered across X posts, online reviews, and forums, often overwhelming and hard to synthesize. Manually sorting through this data to pinpoint recurring issues like poor output quality, complex interfaces, or slow performance takes hours, delaying critical improvements. This fragmented process risks missing key pain points, leading to stagnant user experiences and lost trust. Perplexity Labs tackles this by automating deep web research, aggregating insights, and visualizing trends in minutes, empowering teams to act swiftly and effectively. How to access: (Pro subscription: $20/month) Perplexity Labs can help you: - Aggregate feedback: Pull insights from X, reviews, and web sources into one report. - Visualize trends: Create dashboards to spotlight pain points and themes. - Drive action: Deliver tailored recommendations to enhance user experience. Example Scenario: You're a product manager building an AI image generation app. Here's how Perplexity Labs help you identify gaps in this segment. Prompt: - Create a comprehensive report analyzing user feedback for AI image generation tools by summarizing pain points and recurring themes from X posts, online reviews, and relevant web sources. Focus on identifying common issues such as low-quality outputs, complex or ineffective prompt requirements, slow processing times, lack of customization options, or challenges with user trust and engagement. Organize the findings into a clear, structured report with the following components: - Summary of pain points - Recurring themes dashboard - Actionable recommendations - Assets: Ensure all generated content, such as charts, images, and datasets, is organized in the Assets tab for easy access and download. - Use deep web browsing to gather real-time data from X posts and online reviews, and employ code execution to create the dashboard. The report should be professional, concise, and designed to assist product managers in prioritizing improvements for AI image generation tools. Steps to use in Perplexity Labs: - Access Labs: Log into Perplexity Pro, select Labs mode. - Input prompt: Paste the prompt. - Monitor progress: Labs browses sources and generates a report/dashboard in about 10 minutes. - Review outputs: Explore report, recommendations, and Assets tab for charts. - Refine: Use prompts like, 'Update dashboard with a heatmap for issue trends". What makes Perplexity Labs special? - Integrated workflow: Combines research, analysis, and visualization seamlessly. - Asset hub: Organizes charts and data in the Assets tab for easy access. - Pro efficiency: Delivers complex insights quickly, exclusive to Pro users. Mint's 'AI tool of the week' is excerpted from Leslie D'Monte's weekly TechTalk newsletter. Subscribe to Mint's newsletters to get them directly in your email inbox. Note: The tools and analysis featured in this section demonstrated clear value based on our internal testing. Our recommendations are entirely independent and not influenced by the tool creators. Jaspreet Bindra is co-founder and CEO of AI&Beyond. Anuj Magazine is also a co-founder.

Mint

28 minutes ago

• Mint

Four Indian pharma stocks that may be hit by US pharma tariff threat

Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from

Hans India

39 minutes ago

• Hans India

Strong demand, stable activity in economy

India's economic indicators are becoming more supportive of growth, according to the report released by Motilal Oswal Private Wealth (MOPW) on Friday. The report highlights that several positive trends are emerging on the domestic front, including higher GDP growth, easing inflation, and strong tax GDP grew by 7.4 per cent in the fourth quarter of FY25, which is the highest reading in the last four has remained below 4 per cent for four consecutive months, and GST collections have been rising steadily. These signs indicate strong demand and stable activity in the formal sector of the report also notes that India's policy environment is now moving in a unified direction. Fiscal, monetary, and regulatory policies are all aimed at maintaining growth increased tax exemption limits that came into effect from April 2025 are expected to improve disposable incomes and boost the same time, the government's capital expenditure continues to rise, supporting the investment the global front, the environment remains mixed. In April and May, markets faced worries over tariffs and geopolitical tensions. However, the situation improved with a delay in global tariff implementation and a ceasefire announcement between India and Pakistan. This improved global sentiment has helped global equity markets, with the MSCI World Index reaching record highs. Meanwhile, rising bond yields in Japan and China's shift towards gold show that global investors are moving away from US could become a concern as the US faces refinancing of $9 trillion in debt this a weaker Dollar Index could help emerging markets like India by attracting more foreign investments. In the Indian stock market, valuations have increased as earnings have not grown at the same Nifty-50's one-year forward valuation has risen above its long-term average, and mid and small-cap stocks continue to trade at a premium. This makes careful stock selection and active management more important for investors looking to generate higher returns, the report stated.